Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
$2.22
+1.6%		$2.38
$1.19
▼
$3.60
$159.99M0.36608,324 shs155,842 shs
Biogen Inc. stock logo
BIIB
Biogen
$208.13
+3.1%		$201.39
$127.00
▼
$219.72
$30.74B0.171.29 million shs703,740 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,112.79
-0.8%		$1,153.77
$623.78
▼
$1,249.45
$1.05T0.513.11 million shs2.21 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
+1.40%-0.91%-20.44%-13.49%+61.48%
Biogen Inc. stock logo
BIIB
Biogen
-0.56%+0.84%-6.62%+6.71%+52.95%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.35%-6.31%-7.12%+13.48%+47.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
$2.22
+1.6%		$2.38
$1.19
▼
$3.60
$159.99M0.36608,324 shs155,842 shs
Biogen Inc. stock logo
BIIB
Biogen
$208.13
+3.1%		$201.39
$127.00
▼
$219.72
$30.74B0.171.29 million shs703,740 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,112.79
-0.8%		$1,153.77
$623.78
▼
$1,249.45
$1.05T0.513.11 million shs2.21 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
+1.40%-0.91%-20.44%-13.49%+61.48%
Biogen Inc. stock logo
BIIB
Biogen
-0.56%+0.84%-6.62%+6.71%+52.95%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.35%-6.31%-7.12%+13.48%+47.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
2.33
Hold$8.00261.99% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.56
Moderate Buy$223.8910.27% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,283.6413.73% Upside

Current Analyst Ratings Breakdown

Latest ABOS, LLY, and BIIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/3/2026
Biogen Inc. stock logo
BIIB
Biogen
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$200.00 ➝ $215.00
7/30/2026
Biogen Inc. stock logo
BIIB
Biogen
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$237.00 ➝ $251.00
7/30/2026
Biogen Inc. stock logo
BIIB
Biogen
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$242.00 ➝ $240.00
7/30/2026
Biogen Inc. stock logo
BIIB
Biogen
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$225.00 ➝ $240.00
7/30/2026
Biogen Inc. stock logo
BIIB
Biogen
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$245.00 ➝ $248.00
7/30/2026
Biogen Inc. stock logo
BIIB
Biogen
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$222.00 ➝ $231.00
7/30/2026
Biogen Inc. stock logo
BIIB
Biogen
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$215.00 ➝ $225.00
7/30/2026
Biogen Inc. stock logo
BIIB
Biogen
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$201.00 ➝ $215.00
7/29/2026
Biogen Inc. stock logo
BIIB
Biogen
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
7/29/2026
Biogen Inc. stock logo
BIIB
Biogen
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$300.00
7/15/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$1,500.00 ➝ $1,600.00
(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/A$1.16 per shareN/A
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.03$22.64 per share8.97$124.45 per share1.63
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$72.25B14.71$24.70 per share45.70$28.07 per share40.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$121.33M-$1.86N/AN/AN/AN/A-123.07%-79.41%8/11/2026 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$5.6535.8412.326.208.32%11.18%6.88%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1540.1125.091.4334.98%105.77%23.76%8/5/2026 (Estimated)

Latest ABOS, LLY, and BIIB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$0.39N/AN/AN/AN/AN/A
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.06N/AN/AN/A$20.69 billionN/A
7/29/2026Q2 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.94$3.60+$0.66$0.66$2.46 billion$2.74 billion
5/12/2026Q1 2026
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$0.4028-$0.33+$0.0728-$0.33N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/AN/A
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.61%+15.18%24.58%11 Years

Latest ABOS, LLY, and BIIB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.63%8/14/20268/14/20269/10/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
0.19
4.55
4.55
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.87
1.26
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10

Institutional Ownership

CompanyInstitutional Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
71.01%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
10.20%
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
2072.23 million64.86 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.75 million147.39 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable

Recent News About These Companies

Is Eli Lilly (LLY) Still the Undisputed Leader in the $150 Billion Obesity Drug Market?
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/eli-lilly-lly-still-undisputed-151506170.html
Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly's Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
August 4 at 9:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338330/0/en/Amplia-Signs-Collaboration-Agreement-With-Lilly-Evaluating-Narmafotinib-Plus-Lilly-s-Kras-G12C-Inhibitor-Olomorasib-in-Non-small-Cell-Lung-Cancer.html
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings
August 4 at 8:31 AM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/dividends/26/08/60903490/how-to-earn-500-a-month-from-eli-lilly-stock-ahead-of-q2-earnings-3
Eli Lilly Is Up 7% in 2026 and Has Major Catalysts on the Way. Is the Rally Just Getting Started?
August 4 at 7:50 AM  |  fool.comhttps://www.fool.com/investing/2026/08/04/eli-lilly-is-up-7-in-2026-and-has-major-catalysts/?source=marketbeat&utm_source=marketbeat&utm_medium=feed&utm_campaign=article&referring_guid=bd2fb52b-a4b3-47a0-8d7c-420e9c1cbcd3
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
August 4 at 7:36 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ibio-strengthens-clinical-leadership-appointment-110000323.html
Here's How Much Traders See Eli Lilly Stock Moving After Earnings
August 4 at 7:21 AM  |  investopedia.comhttps://www.investopedia.com/here-is-how-much-traders-see-eli-lilly-stock-moving-after-earnings-lly-q2-fy2026-12032506
Neville Rodie & Shaw Inc. Has $20.66 Million Stock Holdings in Eli Lilly and Company $LLY
August 4 at 6:31 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-neville-rodie-shaw-inc-has-2066-million-stock-holdings-in-eli-lilly-and-company-lly-2026-08-04/
Meadowbrook Wealth Management LLC Increases Stake in Eli Lilly and Company $LLY
August 4 at 6:15 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-meadowbrook-wealth-management-llc-increases-stake-in-eli-lilly-and-company-lly-2026-08-04/
Eli Lilly and Company $LLY Shares Bought by RDA Financial Network
August 4 at 6:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eli-lilly-and-company-lly-shares-bought-by-rda-financial-network-2026-08-04/
Eli Lilly and Company $LLY Position Reduced by Pacer Advisors Inc.
August 4 at 5:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eli-lilly-and-company-lly-position-reduced-by-pacer-advisors-inc-2026-08-04/
Eli Lilly and Company $LLY Shares Bought by CX Institutional
August 4 at 4:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eli-lilly-and-company-lly-shares-bought-by-cx-institutional-2026-08-04/
Eastern Bank Sells 9,169 Shares of Eli Lilly and Company $LLY
August 4 at 3:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eastern-bank-sells-9169-shares-of-eli-lilly-and-company-lly-2026-08-04/
Amplia Therapeutics partners with Lilly on lung cancer combination trial
August 4 at 2:36 AM  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1096463/amplia-therapeutics-partners-with-lilly-on-lung-cancer-combination-trial-1096463.html
More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
August 4 at 2:36 AM  |  finance.yahoo.comhttps://finance.yahoo.com/m/d3f93891-f8de-34f3-b145-44e20e0e7386/more-biotech-m%26a-is-coming%2C.html
JPMorgan names 3 stocks worth buying ahead of August earnings
August 3 at 11:16 PM  |  invezz.comI
Eli Lilly to offer early access to next-gen obesity drug to some patients
August 3 at 7:00 PM  |  reuters.comhttps://www.reuters.com/legal/litigation/eli-lilly-offer-early-access-next-gen-obesity-drug-some-patients-2026-08-03/
Eli Lilly and Company (NYSE:LLY) Shares Down 2.3% - Should You Sell?
August 3 at 5:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/eli-lilly-and-company-nyselly-shares-down-23-should-you-sell-2026-08-03/
FDA Awards Breakthrough Therapy Designation to Lilly’s Olomorasib for Pancreatic Cancer
August 3 at 4:34 PM  |  yahoo.comhttps://www.yahoo.com/news/science/articles/fda-awards-breakthrough-therapy-designation-123238275.html
Eli Lilly’s olomorasib gets FDA breakthrough therapy status for pancreatic cancer
August 3 at 4:34 PM  |  seekingalpha.comhttps://seekingalpha.com/news/4623360-eli-lillys-olomorasib-gets-fda-breakthrough-therapy-status-for-pancreatic-cancer
Top Pharmaceutical Stocks To Consider - August 3rd
August 3 at 2:00 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/top-pharmaceutical-stocks-to-consider-august-3rd-2026-08-03/
Eli Lilly Stock (LLY) Opinions on Upcoming Earnings Release
August 3 at 1:51 PM  |  quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Coastal oil refinery with storage tanks, a gas flare stack, and tankers anchored offshore at dusk.
As the Iran War Resumes, 2 Energy ETFs Ride Oil’s Renewed Rally
By Jessica Mitacek | July 15, 2026
Illustrated data center corridor with server racks and cables leading to a glowing door labeled Anthropic.
Want Anthropic Exposure Before the IPO? These 2 AI Giants Are Already There
By Jessica Mitacek | July 8, 2026
Penguin Solutions logo overlaid on a data center hallway lined with server racks.
Why Penguin Solutions May Be the Smartest AI Infrastructure Stock
By Thomas Hughes | July 8, 2026
AST SpaceMobile logo with a satellite featuring large solar arrays orbiting above Earth in space.
AST SpaceMobile’s Next Launches Could Decide Whether Its Rally Regains Orbit
By Jessica Mitacek | July 13, 2026
Tower Semiconductor logo displayed on a screen with a silicon wafer on a stand in a cleanroom hallway.
Tower Semiconductor’s AI Rally Is Built on a Light-Speed Bet
By Jeffrey Neal Johnson | July 15, 2026
Acumen Pharmaceuticals stock logo

Acumen Pharmaceuticals NASDAQ:ABOS

$2.22 +0.04 (+1.61%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Biogen stock logo

Biogen NASDAQ:BIIB

$208.13 +6.31 (+3.12%)
As of 02:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,112.79 -8.57 (-0.76%)
As of 02:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas